#USA #Rockville #gene therapy #AAVnerGene #AAVone®

AAVnerGene Launches AAVone®2.1: A Breakthrough in Gene Therapy Production

AAVnerGene Inc. has announced a significant leap in gene therapy production with the recent launch of AAVone®2.1, an innovative platform that marks a new generation in the manufacturing of adeno-associated virus (AAV) vectors. This advanced technology is geared towards addressing long-standing challenges faced in the AAV production process such as low productivity and the prevalence of empty capsids.

What is AAVone®2.1?

AAVone®2.1 is a next-generation, single-plasmid AAV production system that achieves approximately 1 x 10¹⁶ genome copies per liter (GC/L) and boasts an impressive over 70% of full capsids at harvest. This represents a remarkable enhancement over its predecessor, AAVone®1.0, and traditional multiple-plasmid systems, which often fall short by producing a high ratio of empty capsids. The platform is not only versatile—proving its efficacy across multiple AAV serotypes—but also seamlessly integrates with existing HEK293 cell lines and manufacturing workflows.

Major Improvements in Quality and Efficiency

The introduction of AAVone®2.1 brings forth numerous improvements in the AAV production process. Firstly, it significantly lowers the demand for plasmids, thereby reducing cell culture volumes, purification loads, and processing steps. This streamlining leads to decreased processing times and lower manufacturing costs while enhancing the overall quality of the AAV vector produced. By tackling crucial limitations in AAV production, AAVone®2.1 sets the stage for scalability in clinical and commercial applications for AAV-based gene therapies.

Qizhao Wang, Ph.D., the Chief Technology Officer at AAVnerGene, highlighted that the manufacturing of AAV remains one of the pivotal technical and economic challenges in the field of gene therapy. Traditional multiple-plasmid systems have supported progress in this area for decades, yet they continue to face limitations—particularly in productivity and the burden of empty capsids that complicate purification processes. AAVone®2.1 addresses these issues with a simplified approach that boosts vector productivity and improves full capsid ratios.

The Importance of Reducing Manufacturing Costs

The commercialization of gene therapy via AAV is fraught with challenges, particularly the high cost of production and the rigorous demands for vector quality and process scalability. According to Daozhan Yu, Ph.D., the CEO of AAVnerGene, AAVone®2.1 has the potential to simplify and reduce the costs associated with AAV manufacturing, paving the way for more AAV gene therapy programs to become clinically and commercially viable. This could significantly alter the landscape of gene therapy accessibility and efficiency.

Collaborative Ventures with Industry Partners

AAVnerGene has licensed its cutting-edge technology to partners, who are launching a variety of AAV-based gene therapy programs using the AAVone®2.1 platform. The company aims to provide enabling technologies that not only surmount manufacturing hurdles but also diminish developmental costs while expanding the portfolio of gene therapy initiatives that can successfully reach patients.

About AAVnerGene Inc.

AAVnerGene is a Maryland-based biotechnology firm dedicated to innovating solutions that address bottlenecks in AAV gene therapy. Their platforms encompass AAVone®, AAV-Q (including potency testing and rcAAV), and ATHENA (which focuses on capsid engineering), all designed to enhance productivity, quality, scalability, and safety in AAV gene therapy development.

For business inquiries or media questions, please contact email protected] or visit [AAVnerGene's official website.

In a period where gene therapy holds massive potential for treating genetic disorders, the introduction of technologies like AAVone®2.1 can play a pivotal role in advancing treatment accessibility and efficacy, changing the lives of countless patients in the process.